Why should new assisted treatment be followed by a pathological assessment?

Newly assisted treatment is a series of pre-surgery anti-oncological treatments, including, inter alia, chemotherapy, decomposition and endocrine treatment. The aim is to reduce the tumor and the difficulty of surgical removal, thereby increasing the success rate of the operation and reducing the risk of relapse and transfer after the operation. The importance of the pathological assessment of new assisted treatment for breast cancer is mainly reflected in the following aspects: By comparing pathological results before and after treatment, doctors can see whether the tumor is decreasing, cancer cell activity is decreasing, and whether there is bad death. This information directly reflects the effects of new assisted treatments. Second, pathological assessments help to guide follow-up treatment decisions. If the neoplasm has reached total pathology after the new assisted treatment, there is a marked difference between the follow-up treatment programme and the patients who have not reached full relief. In addition, pathological assessments can predict the patient ‘ s prognosis. By examining the type of cancer cell, the degree of fragmentation, the extent of immersion and the lymphoma transfer, doctors can assess the risk of relapse and the duration of life. This information is essential for developing individualized treatment plans and psychological support. In the light of the above, the pathological assessment after the new assisted treatment is important to confirm the efficacy of the treatment, to guide the operation, to predict the prognosis, etc. Patients should therefore actively cooperate in the pathological assessment of new assisted treatments in order to obtain more comprehensive treatment information and better treatment outcomes. The assessment of the efficacy of new assisted treatment for breast cancer is a comprehensive process that involves multiple considerations. The following are some of the main assessment methods and indicators: The higher the tumor reduction rate, the better the treatment is. Pathological assessment: a pathological assessment of new assisted treatment can provide a visual assessment of the effects of treatment on cancer cells. To adjust the follow-up treatment. Quality of life: In addition to the objective indicators mentioned above, the quality of life of patients is an important aspect of the assessment of the efficacy of treatment. Newly assisted treatment reduces the patient’s symptoms and improves the quality of life. The combined effect of new assisted treatment can be assessed by means of questionnaires, interviews, etc., to understand how the patient feels during the course of treatment and changes in the quality of life. It is important to note that the specific circumstances of each patient vary, and therefore the assessment of the efficacy of treatment requires a combination of factors and a personalized analysis based on the actual situation of the patient. At the same time, the results of the assessment should be interpreted and directed by a specialist doctor in order to develop more rational and effective treatment programmes.